Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-tar...
Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)
About this item
Full title
Author / Creator
Nam, J L , Villeneuve, E , Hensor, E M A , Conaghan, P G , Keen, H I , Buch, M H , Gough, A K , Green, M J , Helliwell, P S , Keenan, A M , Morgan, A W , Quinn, M , Reece, R , van der Heijde, D M , Wakefield, R J and Emery, P
Publisher
United States: Elsevier Limited
Journal title
Language
English
Formats
Publication information
Publisher
United States: Elsevier Limited
Subjects
More information
Scope and Contents
Contents
Objectives In disease modifying antirheumatic drug (DMARD)-naive early rheumatoid arthritis (RA), to compare the efficacy of methotrexate (MTX) and infliximab (IFX) with MTX and intravenous corticosteroid for remission induction. Methods In a 78-week multicentre randomised controlled trial, double-blinded to week 26, 112 treatment-naive RA patients...
Alternative Titles
Full title
Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1777884372
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1777884372
Other Identifiers
ISSN
0003-4967
E-ISSN
1468-2060
DOI
10.1136/annrheumdis-2013-203440
